NEW YORK, June 29, 2022 /PRNewswire/ -- M.S.Q. Ventures
("MSQ") is pleased to announce that its client, BioLineRx
Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has successfully
entered into a co-development agreement with GenFleet Therapeutics,
Inc., an immuno-oncology focused biopharmaceutical company based in
Shanghai, China, for the
development of Motixafortide in pancreatic ductal adenocarcinoma
("PDAC").
Under the terms of the agreement, GenFleet will design and
execute a randomized Phase 2b
clinical trial that will enroll approximately 200 first-line
metastatic PDAC patients in China.
This randomized controlled study will aim to evaluate the
superiority of Motixafortide in combination with an anti-PD-1 and
chemotherapy compared to chemotherapy alone, the current standard
of care.
"This collaboration is based on the highly encouraging results
from our Phase 2a COMBAT/KEYNOTE-202 study of Motixafortide in
combination with an anti-PD-1 and chemotherapy, which provide
strong support for continued development in this very challenging
disease. With its broad solid tumor oncology pipeline and highly
experienced development team, we believe we have found an
outstanding partner in GenFleet to execute a rigorously designed
randomized Phase 2b trial," said
Philip Serlin, CEO of
BioLineRx. "The MSQ team helped to navigate through the
complexity of cross-border transactions and secured this
transaction by deploying their deep knowledge of the global market.
We are highly impressed with MSQ's "thinking outside the box"
approach and their expertise in deal structuring and
negotiation."
"The results of the COMBAT/KEYNOTE-202 Phase 2a study
demonstrate the benefit of combining the CXCR4 inhibitor
Motixafortide with an anti-PD-1 and chemotherapy in a second-line
setting," said Qiang Lu, Chairman of GenFleet. "We believe that
this combination could be beneficial to patients in a first-line
setting as well, and we hope to confirm this in a randomized trial.
We are thrilled to be partners with BioLineRx in the development of
this late-stage clinical asset, and look forward to initiating this
important trial as quickly as possible. Throughout this journey,
MSQ team has demonstrated professionalism and dedication in helping
both of our teams to reach the finish line in a timely
fashion."
Echo Hindle-Yang, CEO of MSQ,
reflects on the transaction, "This collaboration demonstrates
another excellent example of global co-development, which leverages
each company's regional expertise to accelerate the development of
new treatments. We are excited to see the alliance between
BioLineRx and Genfleet to pursue the treatment of PDAC, which has
proven to be incredibly challenging. I am impressed by Phil's
commitment to developing Motixafortide in PDAC which is also shared
by GenFleet's Dr. Lu. With such a strong commitment from each team,
we believe that patients will benefit from this collaboration. We
are honored to move forward with this cross-border partnership, and
help achieve future success.
About MSQ
M.S.Q. Ventures is a New York-based cross-border
advisory firm that bridges the healthcare industries
globally by offering our deep knowledge, strong network, and local
insights into the China market.
info@msqventures.com
Logo
- https://mma.prnewswire.com/media/1849947/MSQ_Ventures_Logo.jpg